← All trials
NCT01172509
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- Jul 1, 2012
- Completion date
- Jul 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- Berenson-Allen Center for Noninvansive Brain Stimulation BIDMCOverall official - principal investigator
- Berenson-Allen Center for Noninvansive Brain Stimulation BIDMCStudy chair
- Seaside Therapeutics, Inc.Collaborator
- Harvard UniversityStudy director
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.